Study of IPN01203 for advanced solid tumors after immunotherapy
Part of Cancer clinical trials.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your cancer has spread or cannot be removed surgically.
- You have at least one measurable tumor on a CT or MRI scan.
- You have recovered from serious side effects of past treatments (mild side effects like hair loss or nerve issues are okay).
- Your kidneys, liver, and blood counts are good enough.
- You cannot have untreated brain tumors or serious heart, lung, or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.